Key points are not available for this paper at this time.
In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
Paz‐Ares et al. (Tue,) studied this question.